Goldberg Law PC, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Biogen Inc. (“Biogen” or the “Company”) (Nasdaq: BIIB). Investors who purchased or otherwise acquired Biogen shares between July 23, 2014 and July 23, 2015 inclusive (the “Class Period”) are encouraged to contact the firm in advance of the December 23, 2016 lead plaintiff motion deadline.

If you are a shareholder who suffered a loss during the Class Period, click here to participate. In addition, we encourage you to contact Michael Goldberg or Brian Schall, of Goldberg Law PC, 1999 Avenue of the Stars, Suite 1100, Los Angeles, CA 90067, at 800-977-7401, to discuss your rights free of charge. You can also reach us through the firm’s website at http://www.Goldberglawpc.com, or by email at info@goldberglawpc.com.

The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

The complaint alleges that during the Class Period, Biogen issued false and misleading statements concerning the safety profile and growth prospects of Tecfidera, an immunosuppressant that is prescribed to treat multiple sclerosis (“MS”), and Biogen’s main driver of revenues at the time. The Company publicly praised Tecfidera’s attractive safety profile and solid growth trajectory, while aware that the drug weakened the immune system for MS patients, causing physicians to discontinue prescriptions of Tecfidera. On October 22, 2014, Biogen announced the death of a patient linked to Tecfidera. On April 24, 2015, the Company disclosed that the patient death announced in October 2014 was causing Tecfidera sales to grow “at an overall slower rate” but the long-term outlook “remain[ed] strong.” On July 24, 2015, Biogen abruptly cut its revenue guidance in half due to a revised growth expectation for Tecfidera based on safety concerns following the patient death. When this news was announced, shares of Biogen fell in value, causing investors harm.

Goldberg Law PC represents shareholders around the world and specializes in securities class actions and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.